9/6/2022 8:12:07 AM
Eiger Updates On Status Of Peginterferon Lambda COVID-19 Emergency Use Authorization Application
6/8/2022 8:27:53 AM
Eiger BioPharma Announces Multiple Presentations At EASL International Liver Congress 2022
5/20/2022 8:41:06 AM
Eiger Receives Positive CHMP Opinion For Zokinvy As Treatment For Hutchinson-Gilford Progeria Syndrome
4/25/2022 8:17:06 AM
Eiger Publishes Positive Phase 2 Results Of Avexitide In Children With Congenital Hyperinsulinism
12/15/2021 8:15:23 AM
Eiger Reports Positive Analysis & Continuation Of Dosing Of Peginterferon Lambda In Phase 3 Study Of COVID-19 Patients
11/1/2021 8:12:08 AM
Eiger BioPharma Completes Enrollment In Phase 3 D-LIVR Study
9/20/2021 8:10:09 AM
Eiger BioPharma Announces Interim Analysis Of Dosing Of Peginterferon Lambda In Phase 3 TOGETHER Study
8/5/2021 8:19:00 AM
Eiger Unveils FDA Breakthrough Therapy Designation For Avexitide For Congenital Hyperinsulinism Treatment
7/7/2021 8:08:35 AM
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/7/2021 8:05:06 AM
Amedisys Completes Acquisition Of Home Health And Hospice Assets From VNA
7/6/2021 8:07:27 AM
Eiger BioPharma Doses First Patients Dosed With Peginterferon Lambda In Phase 3 TOGETHER Study
6/28/2021 8:16:45 AM
Eiger Announces Presentation Of Positive Phase 2 Results Of Avexitide In Congenital Hyperinsulinism
4/22/2021 8:14:03 AM
Eiger BioPharmaceuticals Appoints Veteran Kim Sablich To Board
2/23/2021 8:15:27 AM
Eiger : Primary And Secondary Endpoints Achieved In Phase 2 PREVENT Study Of Avexitide In Post-Bariatric Hypoglycemia